STARODUBOV, V.I.,
MARCZAK, L.B.,
VARAVIKOVA, E.,
BIKBOV, B.,
ERMAKOV, S.P.,
GALL, J.,
GLENN, S.D.,
GRISWOLD, M.,
IDRISOV, B.,
KRAVCHENKO, M.,
LIOZNOV, D.,
LOYOLA, E.,
RAKOVAC, I.,
VLADIMIROV, S.K.,
VLASSOV, V.,
MURRAY, C.J.L.,
NAGHAVI, M (2018) with disability (YLDs), years of life lost (YLLs),
disability-adjusted life-years (DALYs), and
associated risk
LIU, W.,
ZHUANG, R.,
BAI, X.,
JIA, Z.,
KAPORA, E.,
TAN, W.,
FENG, S. (2020) the effect of ASB16-AS1 on CC via regulating miR-1305. Methods: Differentially expressed lncRNAs
associatedLuo, W.,
Chen, X.,
Ye, L.,
Chen, X.,
Jia, W.,
Zhao, Y.,
Samorodov, A.V.,
Zhang, Y.,
Hu, X.,
Zhuang, F.,
Qian, J.,
Zheng, C.,
Liang, G.,
Wang, Y. (2021) , and kidney dysfunction in diabetic mice. These effects were
associated with a downregulation of TRAF6
Pang, H.Y.,
Chen, X.L.,
Song, X.H.,
Galiullin, D.,
Zhao, L.Y.,
Liu, K,
Zhang, W.H.,
Yang, K,
Chen, X.Z.,
Hu, J.K. (2021) .0001; I2 = 22%). This intervention was also
associated with shorter postoperative stays (MD = − 1.27; 95